Axsome Therapeutics is a biopharmaceutical company that develops and commercializes innovative medicines for central nervous system conditions including depression, sleep disorders, and migraines. The company markets three FDA-approved products: AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for acute migraine treatment, leveraging proprietary formulation and medicinal chemistry technologies to create differentiated therapies with novel mechanisms of action. Axsome generates revenue from these approved products and maintains a development pipeline of candidates in various stages targeting neurological and psychiatric disorders, with a strategic focus on retaining U.S. commercialization rights while partnering internationally.